RANCHO CORDOVA, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that ThermoGenesis, the company’s device subsidiary, will showcase its AutoXpress cellular bioprocessing and BioArchive cryopreservation solutions at the 2017 International Society for Cellular Therapy (ISCT) Annual Meeting being held May 3-6 at the ExCel London Conference Center in London, U.K.
“For the past 25 years, the ISCT Annual Meeting has been among the foremost gatherings of thought leaders in the burgeoning field of cellular therapy, and we look forward to again interacting with colleagues, peers and customers at this year’s event,” said Dr. Xiaochun “Chris” Xu, interim chief executive officer. “As cellular therapy continues to evolve and expand into new areas, such as immuno-oncology, we believe we are well positioned with a suite of solutions that generate higher levels of cell recovery and viability versus competing systems, creating the potential for improved medical outcomes.”
ThermoGenesis’ solutions will be exhibited in Booth #811.
About the International Society for Cellular Therapy
Established in 1992, the International Society for Cellular Therapy is a global society of clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients’ lives worldwide.
About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets. Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics' annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
CONTACT: Company Contact: Cesca Therapeutics Inc. firstname.lastname@example.org Investor Contact: Rx Communications Paula Schwartz 917-322-2216 email@example.com